Check-Cap (NASDAQ:CHEK) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Check-Cap (NASDAQ:CHEK) in a note issued to investors on Wednesday. The firm set a “sell” rating on the medical research company’s stock.

Check-Cap Stock Up 1.0 %

NASDAQ CHEK opened at $0.80 on Wednesday. The stock’s 50-day simple moving average is $0.88 and its two-hundred day simple moving average is $1.07. Check-Cap has a twelve month low of $0.56 and a twelve month high of $3.04. The company has a market capitalization of $4.68 million, a price-to-earnings ratio of -0.27 and a beta of 0.19.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.